Diabetes mellitus – are there possibilities for prevention?
Authors:
prof. MUDr. Pavel Weber, CSc. 1; MUDr. Hana Meluzínová 1; MUDr. František Németh, Ph.D. 2; MUDr. Dana Weberová 1; MUDr. Katarína Bielaková 1
Authors‘ workplace:
Klinika interní, geriatrie a praktického lékařství LF MU a FN Brno
1; Geriatrická klinika, FN L. Pasteura, Prešov
2
Published in:
Geriatrie a Gerontologie 2013, 2, č. 4: 223-226
Category:
Review Article
Overview
Diabetes is a chronic disease – or rather a heterogeneous syndrome – which can be both generally and in old age characterized by hyperglycaemia, lack of insulin action, and a tendency to develop late-onset complications (damage to blood vessels and tissues). It is a manifestation of impaired glucose homeostasis and intermediary metabolism of virtually all levels of the organism. Changes in the internal environment are a hyperglycaemic state induced by both intra- and extracellular factors. As for diabetics, the disease will affect them for the rest of their lives, requiring good compliance and strict adherence to treatment. When poor compensation occurs, serious complications gradually develop, such as visual impairment possibly leading to blindness, kidney failure, amputations of the lower limbs and cardio- and cerebrovascular complications.
Keywords:
diabetes mellitus – ethiopathogenesis – epidemiology – late complications – future perspective – prevention
Sources
1. Kahn CR, King GL, Moses AC et al.: Joslin‘s Diabetes Mellitus. 14th Edition. Joslin Diabetes Center, New York: Lippincott Williams & Wilkins 2005.
2. Holt RIC, Cockram C, Flyvbjerg A et al.: Textbook of Diabetes. 4 edition. Oxford- London: Wiley-Blackwell Science Ltd. 2010.
3. Dan Longo, Fauci A, Kasper D et al.: Harrison’s Principles of Internal Medicine. Volumes 1 and 2, 18th Edition. New York: McGraw-Hill Medical Publishing Division 2011.
4. Bartošovič I, Krajčík Š: Prevalencia chronických chorôb obyvateľov v inštitucionálnej starostlivosti. Slov Lek 2001; 11 (5–6): 234–238.
5. Bartošovič I, Tašká A, Bartošovičová D: Posudzovanie seniorov s ťažkým zdravotným postihnutím. Geriatria 2006; 12 (1): 13–19.
6. Maioli M, Puddu L, Pes GM: Latent autoimmune diabetes in adults. Clin Ter 2006; 157 (1): 69–78.
7. Mohan V, Sandeep S, Deepa B et al.: Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res 2007; 125: 217–230.
8. De Mattia G, Laurenti O, Fava D: Diabetic endothelial dysfunction. Effect of free radical scavenging in type 2 diabetic patients. J Diabetes Complicat 2003; 17 (2 Suppl.): 30–35.
9. Dunger DB, Todd JA: Prevention of type 1 diabetes: what next? Lancet 2008; 372 (9651): 1710–1711.
10. Harrison LC: Vaccination against self to prevent autoimmune disease: the type 1 diabetes model. Immunol Cell Biol 2008; 86 (2):139–145.
11. Harris M: Screening for undiagnosed non-insulin-dependent diabetes. In: Alberti, K.G.M.M. & Mazze R (eds). Frontiers of Diabetic Research: Current Trends in Non-insulindependent Diabetes Mellitus. Elsevier Science Publishers. Amsterdam 1989, str. 119–131.
12. Eastman RC, Siverman R, Harris M et al.: Lessening the burden of diabetes. Diabetes Care 1993; 16 (8): 1095–1102.
13. Knowler WC, Barret-Connor EE, Fowler SE et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002; 346 (6): 393–403.
14. Lipscomb ER, Finch EA, Brizendine E et al.: Reduced 10-year risk of coronary heart. Diabetes Care 2009; 32 (3): 394–396.
15. Li G, Zhang P, Wang J et al.: The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371: 1783–1789.
16. Lindström J, Ilanne-Parikka P, Peltonen et al.: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673–1679.
17. DPP Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346 (6): 393–403.
18. DPP Research Group: 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374 (9702): 1677–1686.
19. Kosaka K, Noda M, Kuzuya T: Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005; 67 (2): 152–162.
20. Ramachandran A, Snehalatha C, Mary S et al.: The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDDP-1). Diabetologia 2006; 49 (2): 289–297.
21. Amundson H, Butcher M, Gohdes D et al.: Translating the Diabetes Prevention Program into practice in the general community. Diabetes Educ 2009; 35 (2): 209–223.
22. American Diabetes Association: Standards of medical care in diabetes—2010 Diabetes Care 2010; Suppl. 32: 11–61.
23. Gerstein HC, Yusuf S, Bosch J et al.: DREAM Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006; 368 (9541): 1096–1105.
24. Chiasson JL, Josse RG, Gomis R et al.: STOP-NIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002; 359 (9323): 2072–2077.
Labels
Geriatrics General practitioner for adults Orthopaedic prostheticsArticle was published in
Geriatrics and Gerontology
2013 Issue 4
Most read in this issue
- Prophylaxis of thromboembolism
- Prophylaxis of post-traumatic epilepsy
- Risk factors for venous thrombosis
- Alzheimer‘s dementia – a 21th century epidemic: can we prevent it?